ENP Newswire -
Release date- 16072014 -
Operational results increased 9.4% and the negative impact of currency was 0.3%. Domestic sales increased 14.9%. International sales increased 4.4%, reflecting operational growth of 5.0% and a negative currency impact of 0.6%.
Net earnings and diluted earnings per share for the second quarter of 2014 were
Excluding these special items, net earnings for the current quarter were
'Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities,' said
The Company increased its earnings guidance for full-year 2014 to
Worldwide Consumer sales of
Domestic sales decreased 0.5% primarily reflecting the divestiture of the sanitary protection business. International sales increased 3.9%, which reflected an operational increase of 5.8% and a negative currency impact of 1.9%.
Positive contributors to operational results were sales of TYLENOL and MOTRIN analgesics; over-the-counter upper respiratory medicines as well as anti-smoking aids;
Worldwide Pharmaceutical sales of
The strong sales results were primarily driven by new products including OLYSIO/SOVRIAD (simeprevir), for combination treatment of chronic hepatitis C in adult patients; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA (canagliflozin), for the treatment of adults with type 2 diabetes and IMBRUVICA (ibrutinib), a kinase inhibitor for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia in patients who have had at least one prior therapy.
Additional contributors to operational sales growth were STELARA (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; REMICADE (infliximab) and SIMPONI/SIMPONI ARIA (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults and PREZISTA (darunavir), a treatment for HIV.
Sales results were negatively impacted by loss of exclusivity for ACIPHEX (rabeprazole), a proton pump inhibitor for gastrointestinal disorders, and CONCERTA (methylphenidate HCI) for the treatment of attention deficit hyperactivity disorder.
During the quarter, the
In addition, the EC granted approval for VOKANAMET, a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet for the treatment of adults with type 2 diabetes; OLYSIO (simeprevir) for the treatment of adult patients with genotype 1 or 4 chronic hepatitis C and for INVEGA (paliperidone ER) to extend its adult indication of schizophrenia to include adolescents aged 15 years and older.
In addition, a supplemental New Drug Application (sNDA) was submitted to the
A Marketing Authorization Application was submitted to the
Worldwide Medical Devices and Diagnostics sales of
Primary contributors to operational growth were hip and trauma products in the Orthopaedics business,
Sales results in the U.S. Diabetes Care business were negatively impacted by price declines associated with the implementation of
During the quarter, the SABER PTA Dilatation Catheter for the treatment of patients with Peripheral Arterial Disease received
Subsequent to the quarter, on
Caring for the world, one person at a time, inspires and unites the people of
Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company's website at www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises. Additional information on
Tel: (732) 524-6623
Tel: (732) 524-6678
Tel: (732) 524-6491
Tel: (732) 524-2034
Most Popular Stories
- Businesses, Investors Pressing for Green Policy
- Iran Digs in on Underground Nuclear Site
- 'The Voice' Sounds Different This Season
- Chrysler and Google Launch Virtual Plant Tour
- Existing Home Sales in U.S. Fell in August
- Lower Used-Car Prices Roil the Auto Industry
- Investors Fret Yahoo's Future, Stock Dips
- NSHMBA to Rebrand With New Name, Logo
- Perry Wants to Skip Court for Foreign Trip
- Hispanic Designer Honored As Rising Star